Brophy DF - Search Results

1

Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.

Brophy DF, Martin EJ, Gehr TW, Best AM, Paul K, Carr ME Jr. Brophy DF, et al. J Thromb Haemost. 2006 Feb;4(2):372-6. doi: 10.1111/j.1538-7836.2006.01731.x. J Thromb Haemost. 2006. PMID: 16420568 Free article.

2

The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis.

Pedro AA, Gehr TW, Brophy DF, Sica DA. Pedro AA, et al. Among authors: brophy df. J Clin Pharmacol. 2000 Apr;40(4):389-95. doi: 10.1177/00912700022009099. J Clin Pharmacol. 2000. PMID: 10761166 Clinical Trial.

3

Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.

Brophy DF, Wallace JF, Kennedy DT, Gehr TW, Holdford DA. Brophy DF, et al. Pharmacotherapy. 2000 Aug;20(8):950-7. doi: 10.1592/phco.20.11.950.35261. Pharmacotherapy. 2000. PMID: 10939556

4

The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.

Brophy DF, Wazny LD, Gehr TW, Comstock TJ, Venitz J. Brophy DF, et al. Pharmacotherapy. 2001 Feb;21(2):169-74. doi: 10.1592/phco.21.2.169.34113. Pharmacotherapy. 2001. PMID: 11213853

5

Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease.

Brophy DF, Ripley EB, Holdford DA. Brophy DF, et al. Expert Opin Pharmacother. 2003 Sep;4(9):1461-9. doi: 10.1517/14656566.4.9.1461. Expert Opin Pharmacother. 2003. PMID: 12943475 Review.

6

Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.

Brophy DF, Martin EJ, Gehr TW, Carr ME Jr. Brophy DF, et al. Am J Kidney Dis. 2004 Aug;44(2):270-7. doi: 10.1053/j.ajkd.2004.04.032. Am J Kidney Dis. 2004. PMID: 15264185

7

Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.

Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME. Brophy DF, et al. J Thromb Haemost. 2004 Aug;2(8):1299-304. doi: 10.1111/j.1538-7836.2004.00789.x. J Thromb Haemost. 2004. PMID: 15304034 Free article.

8

A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease.

Brophy DF, Martin RJ, Gehr TW, Carr ME Jr. Brophy DF, et al. Thromb J. 2005 Mar 29;3(1):3. doi: 10.1186/1477-9560-3-3. Thromb J. 2005. PMID: 15796773 Free PMC article.

9

The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients.

Brophy DF, Martin EJ, Carr SL, Kirschbaum B, Carr ME Jr. Brophy DF, et al. Thromb Res. 2007;119(6):723-9. doi: 10.1016/j.thromres.2006.02.013. Epub 2006 Jun 21. Thromb Res. 2007. PMID: 16793120

10

The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.

Brophy DF, Carr ME Jr, Martin EJ, Venitz J, Gehr TW. Brophy DF, et al. J Clin Pharmacol. 2006 Aug;46(8):887-94. doi: 10.1177/0091270006289975. J Clin Pharmacol. 2006. PMID: 16855073 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters